Systemic Treatment of Gastroesophageal Cancer during SARS-CoV2

Joydeep Ghosh; Sandip Ganguly; Bivas Biswas; Deepak Dabkara; Priyanka Srivastava; Amol Patel; Atul Batra; Prashant Mehta

doi:10.4103/ijmpo.ijmpo_118_20

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 141-143
DOI: 10.4103/ijmpo.ijmpo_118_20

How I Treat

Systemic Treatment of Gastroesophageal Cancer during SARS-CoV2

Joydeep Ghosh

Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

,

Sandip Ganguly

Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

,

Bivas Biswas

Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

,

Deepak Dabkara

Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

,

Priyanka Srivastava

Department of Medical Oncology, Shree Krishna Hospital and Medical Research Centre, Karamsad, Gujarat, India

,

Amol Patel

Department of Medical Oncology, Malignant Diseases Treatment Centre, Army Hospital Research and Referral, New Delhi, India

,

Atul Batra

Department of Medical Oncology, AIIMS, New Delhi, India

,

Prashant Mehta

Department of Medical Oncology, Asian Institute of Medical Sciences, Faridabad, Haryana, India

› Author Affiliations

Abstract

Full Text

References

References
1 Liang W, Guan W, Chen R, Wang W, Li J, Xu K. et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 2020; 21: 335-7
2 https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf Available from: [Last accessed on 2020 Mar 31]
3 Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007; 8: 226-34
4 Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30
5 Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20
6 Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet 2019; 393: 1948-57
7 Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS. et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J Clin Oncol 2012; 30: 268-73
8 Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-21
9 Cao CN, Luo JW, Gao L, Xu GZ, Yi JL, Huang XD. et al. Primary radiotherapy compared with primary surgery in cervical esophageal cancer. JAMA Otolaryngol Head Neck Surg 2014; 140: 918-26
10 Hu G, Wang Z, Wang Y, Zhang Q, Tang N, Guo J. et al. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. Drug Des Devel Ther 2016; 10: 2129-36
11 Zhao X, Ren Y, Hu Y, Cui N, Wang X, Cui Y. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials. PLoS One 2018; 13: e0202185
12 Noronha V, Prabhash K, Joshi A, Patil VM, Talole S, Nakti D. et al. Clinical outcome in definitive concurrent chemoradiation with weekly paclitaxel and carboplatin for locally advanced esophageal and junctional cancer. Oncol Res 2016; 23: 183-95
13 Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46
14 Shin HB, An JY, Lee SH, Choi YY, Kim JW, Sohn SS. et al. Is adjuvant chemotherapy necessary in pT1N1 gastric cancer?. BMC Cancer 2017; 17: 287
15 Guo X, Zhao F, Ma X, Shen G, Ren D, Zheng F. et al. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer 2019; 19: 1125
16 Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-9